The Liver Forum hosted the first in-person meeting of the Pediatric Working Group on March 20, 2017 at the Mayflower Hotel in Washington, DC.
The discussion focused on the need for pediatric natural history data, and the possibility and feasibility of developing a pediatric natural history cohort.
Materials:
Presentations:
- Introduction and Meeting Focus
- Overview and Summary of Identified Gaps
Veronica Miller, Forum for Collaborative Research - Regulatory Approach in Pediatric NAFLD/ NASH
Elmer Schabel, European Medicines Agency - Existing NAFLD/NASH Pediatric Research Across the Atlantic
Panelists:
Ingrid Delaet, Intercept Pharmaceutical
Michael W Fried, University of North Carolina
Piotr Socha, The Children' s Memorial Health Institute - Advantages and Disadvantages of Specific Designs in Developing a Natural History Cohort
Miriam Benedicta Vos, Emory University - Pediatric NAFLD/NASH Natural History Inclusion Criteria
Cynthia Behling, University of California, San Diego - Key Information to Track Disease Progression in Pediatric Trials
Joel Lavine, Columbia University - Retention and Engagement in Pediatric NAFLD/NASH Clinical Trials
Panelists:
Dan Peres, Immuron Limited
Reshma Shringarpure, Intercept Pharmaceuticals
Stavra Xanthakos, Cincinnati Children's Hospital Medical Center - Validation of Non-Invasive Biomarkers in Pediatric NAFLD/NASH Clinical Trials
Panelists:
Keri Hildick, Perspectum Diagnostics
David Kleiner, National Cancer Institute
Dan Peres, Immuron Limited
